Current Liabilities decreased faster than Achieve Life Sciences Inc 's Cash & cash equivalent, this led to improvement in Achieve Life Sciences Inc 's Quick Ratio to 14.81, above Achieve Life Sciences Inc average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 956 to 1555.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV�s has?
What are ACHV�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACHV/financial-strength

https://api.csimarket.com/api/v1/companies/ACHV/fundamentals

https://api.csimarket.com/api/v1/companies/ACHV/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ACHV Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	39.88 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	318.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	14.81	Subscribe	Subscribe	Subscribe	Subscribe
ACHV's Total Ranking	# 1555	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-93.11 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-38.31 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 8
Healthcare Sector	# 543
Overall Market	# 1555

Quick Ratio Statistics
High	Average	Low
12.12	4.57	0.72
(Sep 30 2020)		(Dec 31 2023)

Financial Statements
Achieve Life Sciences Inc 's Current Liabilities	$ 14 Millions	Visit ACHV's Balance sheet
Achieve Life Sciences Inc 's Cash & cash equivalent	$ 202 Millions	Visit ACHV's Balance sheet
Source of ACHV's Sales		Visit ACHV's Sales by Geography

Cumulative Achieve Life Sciences Inc 's Quick Ratio

ACHV's Quick Ratio for the trailling 12 Months

ACHV Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	622.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	268.58 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	2.56	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 459	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	34.83 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ACHV Financial Strength Comparisons >> Go to Compare ACHV Quick Ratio to its Competitors

On the trailing twelve months basis ACHV Cash & cash equivalent more than doubled by 318.83 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Achieve Life Sciences Inc 's Quick Ratio to 2.56, Quick Ratio remained below ACHV average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Achieve Life Sciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2698 to 3925.

Explain Quick Ratio?
How much Cash & cash equivalents ACHV�s has?
What are ACHV�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 891
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.14	3.24	0.5
(Dec 31 2020)		(Sep 30 2016)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Achieve Life Sciences Inc	14.81	$ 201.518 Millions	$ 13.610 Millions
Celldex Therapeutics inc	10.75	$ 650.319 Millions	$ 60.517 Millions
Intellia Therapeutics Inc	5.90	$ 474.110 Millions	$ 80.306 Millions

Date modified: 2026-11-11T13:30:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.